Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513734 | 0.96 | CKS1B (0.44) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL513733 | 0.96 | CKS1B (0.44) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL512326 | 0.94 | GPR119 (0.42) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL512855 | 0.94 | GPR119 (0.42) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL512327 | 0.94 | GPR119 (0.42) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL513481 | 0.89 | GPR119 (0.43) | GPR119CKS1BSKP1SKP2SCD5 | |
| SCHEMBL513177 | 0.81 | HDAC4 (0.53) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL387529 | 0.78 | CKS1B (0.56) | GPR119CKS1BSKP1SKP2SCD5 | |
| SCHEMBL18280165 | 0.77 | USP30 (0.47) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL1473227 | 0.76 | GPR119 (0.51) | GPR119GRM5CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GPR119 674/4885GRM5 2/4885CKS1B 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.